Abstract. To achieve sufficient antitumor activity for colorectal carcinoma, optimization of the therapeutic regimen is of great importance. The aim of the present study was to investigate the effects of polyethylene glycol (PEG)-liposomal oxaliplatin (L-OHP) on the induction of apoptosis in human colorectal cancer SW480 cells and how the nuclear factor-κB (NF-κB) pathway may contribute to mediating PEG-liposomal L-OHPinduced apoptosis. PEG-liposomal L-OHP was prepared and used to treat colorectal cancer SW480 cells. SW480 cell uptake of liposomes was observed by laser focus or SEM. Apoptosis was measured by flow cytometry (FCM) and terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay. Expression of NF-κB, Bcl-2, Bax and activated caspase-3 (P17) was examined by western blot analyses. The results indicated that PEG-liposomal L-OHP induced apoptosis. When pretreated with pyrrolidine dithiocarbamate (PDTC), PEG-liposomal L-OHP induced a significant apoptotic response. Moreover, apoptosis was associated with concentration of PDTC. Expression of protein p-P65, Bcl-2 was downregulated, but Bax and P17 were upregulated. These findings indicate that PEG-liposomal L-OHP enhances the anticancer potency of the chemotherapeutic agent. Moreover, NF-κB signaling pathways may contribute to mediating PEG-liposomal L-OHP-induced apoptosis.
Introduction
Colorectal cancer (CRC) is a common type of malignant tumor with a high rate of morbidity and mortality. Early detection of CRC results in radical resection of the tumor in the majority of cases. However, radical resection is curative for only ~50% of the patients who will present local recurrence or distant metastases (1) . The survival rate of patients with metastatic CRC (mCRC) has significantly improved with applications of molecularly targeted drugs, such as oxaliplatin (L-OHP), and has led to a substantial improvement in the overall survival rate. Chemotherapy drugs may exist for pathological parts of non-specific selection and result in the decrease of curative effect and side-effects on the body (2, 3) .
Liposomes, as carriers of chemotherapeutic agents, can alter the distribution of these agents within the body and decrease drug toxicity (4, 5) . Therefore, drug-loaded liposomes offer a new approach to the treatment of CRC. The polyethylene glycol (PEG) modification increases the affinity of liposomes for cancer cells and thus increases the cellular uptake of drugs. Cellular uptake of PEG-liposomal L-OHP induces bioactive changes in cells, resulting in apoptosis.
The transcription factor nuclear factor-κB (NF-κB) is a dimeric complex composed of members of the Rel protein family, which includes p65 (RelA), p105/p50, p100/p52, RelB, c-Rel and the viral oncoprotein (v-Rel) (6) . In its classic form, NF-κB is a dimer that consists of the transcriptionally inactive p50 subunit and the p65/RelA (p65) subunit. NF-κB is a transcription factor that participates in proliferation and metastasis (7) (8) (9) . The abnormality of NF-κB is closely associated with human malignant tumor and different molecular modification of tumor cells results in abnormal activation regulation of NF-κB which loses its inducibility, thus remaining at an activated state, leading to abnormal regulation of apoptosis, cell cycle, adherence and metastatic genes by NF-κB (10, 11) . NF-κB participates in the transcription and regulation of multiple cell factors in the apoptotic pathway (11, 12) . Pyrrolidine dithiocarbamate (PDTC), a selective NF-κB inhibitor, has been used more widely in experimental study as the inhibitor of NF-κB for the treatment of inflammatory diseases (13) . Moreover, it has been reported that PDTC could induce apoptosis via inhibition of NF-κB activation (14, 15) .
In the present study, we investigated the effect of PEG-liposomal L-OHP on apoptosis, as well as regulation of apoptotic cell death by NF-κB, and we prepared PEG modified L-OHP liposomes to treat SW480 cells of human colorectal cancer in an effort to study the apoptosis. Cell culture, cell uptake of liposomes observed by laser focus or scanning electron microscopy (SEM). Dio-labeled PEG-liposomes and PEG-liposomal L-OHP were prepared, as previously described (16) . Human colorectal cancer SW480 cells in the logarithmic growth phase were trypsinized and incubated on glass slides (5x10 3 /slide) in 1 ml of RPMI-1640 medium containing 10% FBS and pre-incubated for 24 h. After removal of the culture medium, 1 ml of fresh medium containing the Dio-labeled PEG-liposomes (2 µmol/ml) was added, followed by incubation at 37˚C. At 8 h post-incubation, the cells were washed twice with cold phosphate-buffered saline (PBS) and fixed with freshly prepared 4% paraformaldehyde (dissolved in pH 7.4 PBS). The cellular uptake of Dio-labeled PEG-liposomes was determined by measuring fluorescence and by SEM.
Materials and methods

Reagents
Immunofluorescence and flow cytometry (FCM) evaluate cellular calcium ion. The cells were placed in wells of a 6-well plate and glass slides incubated for 24 h, respectively. The cells were treated with PEG-liposomal L-OHP (containing 28 µg/ ml L-OHP), PEG-liposomal L-OHP + PDTC (10 µmol/l) or PEG-liposomal L-OHP + PDTC (20 µmol/l) for 12 h, with no treatment as a control. After treatment, the culture medium was removed and washed by PBS. The cell glass slides were fixed with freshly prepared 4% paraformaldehyde, incubated with calcium ion fluorescent probe and evaluated for laser focus. The cells in 6-well plates were trypsinized, collected and fixed with 70% ice-cold ethanol overnight at 4˚C. Cells were centrifuged, re-suspended in 400 µl 1X binding buffer (>1x10 6 /ml) and incubated with calcium ion fluorescent probe (final concentration 5 nmol/ml) in the dark for 1 h. The cells were washed with PBS and resuspended in 200 µl, and analyzed using a BD FACSCalibur (BD Biosciences).
Tagged deoxynucleotide transferase labeling. SW480 cells (5x10 3 /slide) were incubated on glass slides for 24 h, treated for 12 h with PEG-liposomal L-OHP, PEG-liposomal L-OHP + PDTC (10 µmol/l) or PEG-liposomal L-OHP + PDTC (20 µmol/l) and fixed in freshly prepared 4% paraformaldehyde (PFA; dissolved in pH 7.4 PBS) for 30 min at room temperature and finally washed with PBS, as described previously (17) . Cells treated with DNase I, which fragments the DNA, served as positive controls.
Western blot analysis. The cells were collected and lysed and the protein concentration of each sample was determined using the Bradford dye-binding method. Protein samples (50 µg) were electrophoresed on SDS/12 and 15% PAGE gels and transferred to PVDF membranes (Millipore). The membranes were incubated overnight at 4˚C with rabbit antibodies to Bcl-2, Bax, activated caspase-3 (1:500) and an anti-β-actin antibody (1:500), followed by incubation at room temperature for 1 h with a horseradish peroxidase (HRP)-labeled goat anti-rabbit secondary antibody added drop-wise concurrently with the enhanced chemiluminescence illuminating agent (Immobilon ™ Western Chemiluminescent HRP Substrate, kit no. WBKLS0100). Finally, the membranes were visualized using a Bio-Rad system.
Statistical analyses.
All values are expressed as means ± SD using SPSS17.0 software. Experimental results were analyzed by the Student's t-test. P<0.05 was considered as significant for values obtained for treated compounds compared with controls.
Results
Cellular uptake of liposomes.
To study the conjugated effects of the cellular uptake of liposomes, confocal microscopy and scanning electron microscopy were adopted, respectively. Confocal microscopy demonstrated that after incubation in medium containing Dio-labeled liposomes for 4 h, many of the PEG-liposomes conjugated with cells and aggregation of liposomes within cells (Fig. 1A-C) . Also, scanning electron microscopy demonstrated that PEG-liposomes adhered to the cell surface (Fig. 1D) .
Change of cellular calcium ion. Apoptosis signal transduction pathway in cells, calcium ions which activate apoptosis performer caspase-3, and hydrolysis of various cellular components lead to cell apoptosis. Cells were treated with PEG-liposomal L-OHP, and the change of calcium ion was (Figs. 2 and 3) .
Apoptosis analysis.
To establish the cytotoxic effect of PEG-liposomal L-OHP, apoptosis was assayed by TUNEL. The result demonstrated that PEG-liposomal L-OHP induced marked apoptotic death of SW480 cells, compared with control (Fig. 4B) . However, pretreatment with PDTC led to strong detection of apoptosis in SW480 cells (Fig. 4C-D) .
Expression protein of NF-κB (P65).
The phosphorylated NF-кB (p-P65) is able to translocate to the nucleus, activating genes involved in tumor cell proliferation and survival. To determine whether apoptosis is enhanced, after cells were pretreated with NF-κB inhibitor, total protein was extracted from the SW480 cells. The western blot results showed that protein of p-P65 was downregulated, compared with every other group, P<0.05. However, the total protein of P65 was almost unchanged, compared with every other group, P>0.05 (Fig. 5) .
Expression of pro-apoptotic and anti-apoptotic proteins.
Bcl-2, Bax, caspase-3 are associated with apoptosis, necrosis and autophagy and regulate all major types of cell death. To establish the cytotoxic effect of PEG-liposomal L-OHP, after pretreatment with various concentrations of NF-κB inhibitor, apoptosis was assayed by western blot analysis. The results showed Bcl-2 was downregulated. However, Bax and caspase-3 were upregulated, compared with every other group, P<0.05 (Fig. 6 ).
Discussion
The nature of the active species generated in vivo, uptake, efflux, intracellular trafficking or insufficient diffusion in tumor tissues, lead to cytotoxic drugs having no target selectivity between normal body tissues and pathological sites (18) , resulting in decreased curative effects and increased toxicity for certain chemotherapeutic agents.
The ideal therapy is to deliver the drugs directly to pathological sites. PEG-modified liposomes have been used as a carrier of anticancer drugs to enhance the affinity of anticancer drugs to cancer cells and uptake of anticancer drugs by cancer cells (19) (20) (21) . Our in vitro study revealed uptake of PEG-liposomes by cancer cells at 2 h, which increased with time of exposure and accumulation of a great amount of liposomes within the cells by fluorescence and SEM. The results are similar to those reported by Gabizon and Papahadjopoulos, and Gabizon (22, 23) . Accordingly, FCM showed that compared with PEG-liposomal L-OHP, the same dosage of PEG-liposomal L-OHP had a significantly greater impact on apoptotic cell death, after pretreatment with PDTC, the plasma Ca 2+ level was consistently higher (Fig. 3) . Moreover, we found that TUNEL experiments showed apoptotic death of SW480 cells was also consistently increased. PEG-liposomal L-OHP degraded in cells after pinocytosis; furthermore, the intracellular drug release enhanced active drug level within cells and slowed down drug efflux, therefore, liposome entrapment of chemotherapeutics represents its dual effect on tumor cells (24) (25) (26) .
NF-κB, a complex of proteins, is a widespread transcription factor of eukaryotic cells with extensive actions and is involved in cellular inflammatory and apoptotic responses (27) . NF-κB plays a key role in regulating apoptotic cell death. Our study showed that in the liposomal L-OHP-treated group, the apoptotic cells increased (Fig. 4B) . To further explain the role of NF-κB in regulating apoptotic cell death, the tumor cells were administered PDTC pretreatment, which resulted in increased apoptotic cell death ( Fig. 4C and D) . However, the expression protein of NF-κB was markedly suppressed by PDTC pretreatment, P17, Bax and Bad showed an upward trend (Figs. 5 and 6 ). This may be explained by the selective NF-κB inhibition mechanism of PDTC. Activated NF-κB is highly expressed in tumor cells (28, 29) ; the decrease of the activity of NF-κB inhibits the expression of Bcl-2 and Bax (30, 31) , predominantly seen in cytoplasm, and is highly expressed in many refractory tumors or those with poor prognosis such as gastric carcinoma and intestinal carcinoma.
Bcl-2 and Bax are members of the Bcl-2 family (32). They are associated with apoptosis, necrosis. Bcl-2 is an anti-apoptotic protein and guardian of the outer membrane. In contrast, Bax is a proapoptotic protein that induces mitochondrial outer membrane permeabilization, causing the release of caspase activating proteins and it preserves its integrity by opposing Bcl-2. The downregulation of Bcl-2 and upregulation of Bax and induced activation of caspase-3 through upregulation Figure 6 . Expression of protein Bcl-2, Bax and caspase-3. Bcl-2 is an anti-apoptotic protein and guardian of the outer membrane and it preserves its integrity by opposing Bax. After treatment, the total cell extract was prepared, respectively. The protein levels were determined by western blot analysis. Data are representative of three experiments (means ± SD). of intracellular apoptotic pathway (32, 33) , results in final apoptotic cell death (34, 35) . In the present study, these results indicated that NF-κB plays a role in mediating regulation L-OHP PEG-liposome-induced aptoptotic cell death. PDTC was demonstrated to suppress the activation of NF-κB and to ameliorate the cell death of SW480. Moreover, apoptosis was correlated with concentration of PDTC. Therefore, the results obtained in the present study indicate that the inhibition of NF-κB activation by PDTC in the PEG-liposomes L-OHP is likely to be associated with the blocking of NF-κB signal pathway, the downregulation of Bcl-2 expression and upregulation of Bax or caspase-3 expression.
In conclusion, the experiments presented in this report indicate that PEG-liposome-targeting approaches represent a general framework for developing more effective cancer therapies. Liposome entrapment of L-OHP enhanced its anticancer potency. PDTC can enhance the cell apoptosis induced by PEG-liposomes. Inhibition of NF-κB activation increases the antitumor effect of the antitumor agents. The dual treatment regimen is of great significance for the treatment of colorectal cancer. The success of specific combinations of targeted therapies may likely depend on the specificity and efficacy of each individual targeted therapy.
